Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Rajeka Lazarus; Benedicte Querton; Irena Corbic Ramljak; Shailesh Dewasthaly; Juan Carlos Jaramillo; Katrin Dubischar; Michael Krammer; Petronela Weisova; Romana Hochreiter; Susanne Eder-Lingelbach; Christian Taucher; Adam Finn; Claire Bethune; Marta Boffito; Marcin Bula; Fiona M Burns; Rebecca Clark; Dileep Dasyam; Simon Drysdale; Saul Faust; Effrossyni Gkrania-Klotsas; Christopher Green; Hana Hassanin; Paul Heath; Amardeep Heer; Toby Helliwell; Anil Hormis; Philip Kalra; Rajeka Lazarus; Ed Moran; John Ndikum; Iain Page; David Price; Nick Probert; Mahadev Ramjee; Tommy Rampling; Harpal S Randeva; Stephen Ryder; John Steer; Emma Thompson; David Torku

The Lancet Infectious Diseases (2022) - Comments
pubmed: 36075233 doi: 10.1016/s1473-3099(22)00502-3 issn: 1473-3099 issn: 1474-4457

Rajeka Lazarus, Benedicte Querton, Irena Corbic Ramljak, Shailesh Dewasthaly, Juan Carlos Jaramillo, Katrin Dubischar, Michael Krammer, Petronela Weisova, Romana Hochreiter, Susanne Eder-Lingelbach, Christian Taucher, Adam Finn, Claire Bethune, Marta Boffito, Marcin Bula, Fiona M Burns, Rebecca Clark, Dileep Dasyam, Simon Drysdale, Saul Faust